Jefferies is assuming coverage of Avanir Pharmaceuticals AVNR with a $3.50 price target and a Hold rating.
“AVNR markets Nuedexta, a low-dose combination of dextromethorphan and quinidine, for pseudobulbar affect, a disorder of laughing or crying that can accompany neurological disease,” Jefferies writes. “While the market is large, initial sales have been slow and signal significant physician and patient education is needed.”
Avanir Pharmaceuticals closed Thursday at $4.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in